Proyección de los nuevos antihistamínicos

Allergologia et Immunopathologia

Volumn 28, Issue 3, 2000, Pages 143-152

  Eseverri, J L ^a   Marin A Ma ^a  

^a NONE

Author keywords

Antihistamines; Asthma; Patients

Indexed keywords

ANTIASTHMATIC AGENT; ANTIHISTAMINIC AGENT; CYTOCHROME P450; ISOENZYME; NONSTEROID ANTIINFLAMMATORY AGENT; ASTEMIZOLE; CYTOCHROME P450 3A4; DEBRISOQUINE 4 HYDROXYLASE; FEXOFENADINE; KETOCONAZOLE; PHENACETIN O DEETHYLASE; TERFENADINE;

ADULT; ASTHMA; CHEMICALLY INDUCED DISORDER; CHILD; DRUG ANTAGONISM; DRUG CONTRAINDICATION; DRUG EFFECT; FEMALE; HEART DISEASE; HEART MUSCLE CONDUCTION SYSTEM; HUMAN; INFANT; MALE; METABOLISM; NEUTROPHIL CHEMOTAXIS; NEWBORN; PREGNANCY; PRESCHOOL CHILD; REVIEW; CARDIOTOXICITY; CONFERENCE PAPER; DRUG METABOLISM; LIVER METABOLISM;

ADULT; ANTI-ASTHMATIC AGENTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASTHMA; CHEMOTAXIS, LEUKOCYTE; CHILD; CHILD, PRESCHOOL; CYTOCHROME P-450 ENZYME SYSTEM; FEMALE; HEART CONDUCTION SYSTEM; HEART DISEASES; HISTAMINE ANTAGONISTS; HUMANS; INFANT; INFANT, NEWBORN; ISOENZYMES; MALE; PREGNANCY;

EID: 0033917690     PISSN: 03010546     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (74)

1. White MV. The role of histamine in allergic diseases. J Allergy Clin Immunol 1990;28:599-605.
2. Rimmer SJ, Church MK. The pharmacology and mechanisms of action of histamine H1-antagonists. Clin Exp Allergy 1990;20(supp2):3-17.
3. Eberhart LH, Seeling W, Bopp TI, Morin AM, Georgieff M. Dimenhydrinate for prevention of post-operative nausea and vomoting in female in-patients. Eur J Anaesthesiol 1999;16:284-9.
4. Kay GG, Harris AG. Loratadine: a non-sedating antihistamines: Review of its effects on cognition, psycomotor performance, mood and sedation. Clin Exp Allergy 1999;29suppl 3:147-50
5. EAACI position paper: The clinical safety of H1-receptor antagonists. Allergy 1996;51:666-75.
6. Horak F, Stubner UP. Comparartive toleratbility of second generation antihistamine. Drug Saf 1999;20:385-401.
7. Food and Drug Administration (FDA). Warnings issued on nonsedating antihistamines terfenadine and astemizole. JAMA 1992;268:705
8. Mazzotta P, Loebstein R, Koren G. Treating allergic rhinitis in pregnancy. Safety considerations. Drug Saf 1999;20:361-75.
9. Hilbert J, Radwanski E, Affrime MB, Perentesis G, Symehowicz S. Excretion of loratadine in human breast milk. J Clin Pharmacol. 1988;28:234-9.
10. Ito S, Blajchman A, Stephenson M,. Eliopoulos C, Koren G. Prospective follow-up of adverse reactions in breast-fed infants exposed to maternal medication. Am J Obstet Gynecol 1993;168:1393-9.
11. Slater JW, Zechnich AD, Haxby DG. Second-generation antihistamines. A comparative review. Drugs 1999;57:31-47.
12. Delgado LF, Pferferman A, Sole D, Naspitz CK. Evaluation of the potencial cardioxicity of the antihistamines terfenadine,astemizole,loratadine, and ceterizine in atopic children. Ann Allergy Asthma Immunol 1998;80:337-8.
13. Lamberg TS, Kivisto KT, Neuvonen PJ. Lack of effect of terfenadine on the pharmacokinetics of the CYP3A4 substrate buspirone. Pharmacol Toxicol 1999;84:165-9.
14. Jones BC, Hyland R, Ackland M, Tyman CA, Smith DA. Interaction of terfenadine and its priamry metabolites with cytochrome P450 2D6. Drug Metb Dispos 1998;26:875-2.
15. Wong SL, Cao G, Granneaman GR. Lack of CYP3A inhibition effects of sertindole on terfenadine in healthy volunteers. J Clin Pharmacol Ther 1998;36:146-51.
16. Brannan MD, Reidenberg P, Radwansky E, Shneyor L, Lin CC, Coyen MV et al. Loratadine administered concomitantly with erytromycin: pharmacokinetic and electrocardiographic evolutions. Clin Pharm Ther 1995. p. 269-78.
17. Honig PK, Wortham DC, Lazarev D, Cantilena LR. Grapefruit juice alters the systemic bioavailability and cardiac repolarization of terfenadine in poor metabolizers of terfenadine. J Clin Pharmacol 1996;36:345-51.
18. Moss AJ, Chaikin P, Garcia JD, Gillen M, Roberts DJ, Morganroth J. A review of the cardiac systemic side-effects of antihistamines: ebastine. Clin Exp Allergy 1999;29 supl 3:200-5.
19. Hey JA, Affrime M, Cobert B, Kreutner W, Cuss FM. Cardiovascular profile loratadine. Clin Exp Allergy 1999;29 suppl 3:197-9.
20. DuBuske LM. Second-generation antihistamines: the risk of ventricular arrhythmias. Clin Ther 1999;21:281-95.
21. Warin RP. Torsades de Pointes complicating treatment with Terfenadine. Br Med J 1991;303:6793-8.
22. Berul CL, Morad M. Regulation of potassium channels by non-sedating antihistamines. Circulation 1995;91:2220-5.
23. Rampe D, Murawsky MK. Blockade of the human cardiac K+ channel Kv1.5 by the antibiotic erythromycin. Arch Pharmacol 1997;355:743-50.
24. Vosperian VR, Zhou Z, Mohammad S, Hoon TJ, Studenik C, January CT. Torsade de pointes with an antihistamine metabolite: potasium channel blockade with desmethylastemizole. J Am Coll Cardiol 1996;28:1556-61.
25. Honig PK, Woosley RL, Zamani K, Conner DP, Centilena LR. Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant adminstration of erytromycin. Clin Pharmacol Ther 1992; 52:231-8.
26. Crumb WJ. Rate-dependent blockade of a potassium current in human atrium by the antihistamine loratadine. Br J Pharmacol 1999;126:575-80.
27. De Abajo FJ, Rodriguez LA. Risk of ventricular arrhytmias associated with nonsedating antihistamine drugs. Br J Clin Pharmacol 1999;47:307-13.
28. Pratt CM, Mason J, Russell T, Reynolds R, Ahlbrandt R. Cardiovascular safety of fexofenadine HCl. Am J Cardiol 1999;83:1451-4.
29. Ridout SM, Tariq SM. Cetirizine overdose in a young child. J Alleregy Clin Immunol 1997;99:860-1.
30. Hoppu K, Tikanoja T, Tapanainen P, Remfs M, Saarenpaa-Heikkila O, Kouvalainen K. Accidental astemizole overdose in young children. Lancet 1991;338:538-40.
31. Davies AJ, Harindra V, McEwan A, Ghose RR. Cardiotoxic effect with convulsuions in terfenadine overdose. Br Med J 1989. p. 298-325.
32. Clark A, Love H. Astemizole induced ventricular arrhythmias: an unexpected cause of convulsions. Int J Cardiol 1991; 33:165-6.
33. Bedford TA, Rowbothan DJ. Cisapride: drug interactions of clinical significance. Drug Ssf 1996;15:167-75.
34. Honig PK, Wortham DC, Zamani K, Conner DP, Mullin JC, Centilena LR. Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences. JAMA 1993;269:15134-18.
35. Honig PK, Wortham DC, Hull R, Zamani K, Smith SE, Cantilena LR. Itroconazole affects single-dose terfenadine pharmacokinetics and cardiac repolarization pharmacodynamics. J Clin Pharmacol 1993;33:1201-6.
36. Pechadre JC, Vernay D, Trolese JF, Bloom M, Dupont P, Rihoux JP. Comparison of the central and peripheral effects of cetirizine and terfenadine. Eur J Clin Pharmacol 1988;35:255-9.
37. Perchadre JC, Beudin P, Eschalier A, Trolese JF, Rihoux JP. Comparison of the central and peripheral effects of cetirizine and loratadine. J Int Med Res 1991;19:289-95.
38. Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR. The cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice. Eur J Pharmacol 1997; 52:311-5.
39. Spencer JD. Drug interactions with grapefruit: whose responsibility is it to warn the public. Clin Pharmacol Ther 1997;61:395-400.
40. Rau SE, Bend JR, Tran LT, Arnold MD, Spence JD, Bailey DG. Inhibition of terfenadine metabolism by co-administration of grapfruit juice in humans Clin Invest Med 1995;suppl:95.
41. Amsellem C, Czarlewski W, Lagarde M, Pacheco Y. Inhibitory effect of loratadine on leukotriene B4 production by neutrophils either alone or during interaction with human airway epithelial cells. Pulm Pharnmacol Ther 1998;11:245-52.
42. Ferguson AC, Whitelaw M, Brown H. Correlation of bronchial eosinophil and mas cell activation with bronchial hyperresponsiveness in children with asthma. J Allergy Clin Immunol 1992;90:609-13.
43. Togias AG, Nacleiro RM, Warner J, Proud D, Kagey-Sobotka A, Nimmagadda I et al. Demonstration of inhibition of mediator release from human mast cells by azatadine base. JAMA 1986;255:225-9.
44. Bousquet J, Rihoux JP, Chanal I, Michel FB. Comparison of the inhibitory activity of cetirizine and azelastine on skin test and nasal challenge J.Allergy Clin Immunol 1988;82:881-7.
45. Nacleiro RM, Proud D, Kagey-Sobotka A, Freidhoff L, Norman PS, Lichstenstein LM. The effect of cetirizine on early allergic response. Laringoscope 1989;99:596-9.
46. Proud D, Kagey-Sobotka A, Nacleiro RM, Lichstenstein LM. Pharmacology of upper airways challenge. Int Archs Allergy Appl Immunol 1987;82:493-7.
47. Linder A, Strandberg K, Deuschl H. Variations in histamine concentration in nasal secretion in patients with allergic rhinitis. Allergy 1988;43:119-26.
48. Reveuz J, Gabison G, Michaut S. Anti-degranulant action of mequitazine in a cutaneus model. J Invest Dermatol 1989;92:143.
49. Brunet C, Bedart PM, Hebert J. Effect of H1-antihistamine drug regimen on histamine release by non lesional skin mast cells of patients with chronic urticaria J Allergy Clin Immunol 1990;86:787-93.
50. Michel L, De Vos C, Dubertret L. Ceterizine effects on the cutaneous allergic reaction in humans. Ann Allergy 1990;65:512-6.
51. Fadel R, Herpin-Richard N, Rihoux JP, Henocq E. Inhibitory effect of cetirizine 2 HCl on eosinophil migration in vivo. Clin Immunol 1988;82:101-9.
52. Michel L, De Vos C, Rihoux JP, Burtin C, Benvenisye J, Dubertret L. Inhibitory effect of oral cetirizina on in vivo antigen-induced histamine and PAF-acether release and eosinophil recruitment in human skin. J Allergy Clin Immunol 1988;82:101-9.
53. Fadel R, Herpin-Richard N, Dufresne F, Rihoux JP. Pharmacological modulation by cetirizine and loratadine of antigen and histamine-induced skin weals and flares, and accumulation of eosinophiles. J Int Med Res 1990;18:366-71.
54. Bierman CW, Maxwell D, Rytina ED, Emanuel MB, Iee TH. Effect of H1-receptor blocade on late cutaneous reactions to antigen. A double-blind controlled study. J Allergy Clin Immunol 1991;87:1013-9.
55. Fadel R, Herpin-Richard N, Borgon A, Rassemont R, Rihoux JP. In vivo effects of ceterizine on cutaneous reactivity and eosinophil migration induced by platelet activating factor (PAF-acether) in man. J Allergy Clin Immunol 1990;86:314-20.
56. Redier H, Chanez P, De Vos C, Rifai N, Clauzel AM, Michel FB et al. Inhibitory effect of cetirizine on the bronchial eosinophil recruitment induced by allergen inhalation challenge in allergic patients with asthma. J Allergy Clin Immunol 1992;90:215-24.
57. Juhlin L, Rihoux JP. Effect of cetirizine on cutaneous reactions to PAF, kallikrein and serum in patients with chronic urticaria. Acta Derm Venereol 1990;70:151-3.
58. Juhlin L, Pihl-Lundin I. Effects of antihistamine on cutaneous reactions and influx of eosinophils after local injection of PAF, kallikrein,compound 48/80 and histamine in patients with chronic urticaria and healthy subjects. Acta Derm Venereol 1992;72:197-200.
59. Arnoux B, Denjean A, Page CP, Nolibe D, Morley J, Benveniste J. Accumulation of platelets and eosinophils in baboom lung after PAF-acether challenge. Am Rev Respir Dis 1988;137:855-60.
60. Haampel FC, Martin BG, Dolen J, Travers S, Karcher K, Holton D. Efficacy and safety of levocabastine nasal spray for seasonal allergic rhinitis. Am J Rhinol 1999;13:55-62.
61. McNeely W, Wiseman LR. Intranasal azelastine. A review of its efficacy in the management of allergic rhinitis. Dugs 1998;56:91-114.
62. Giede TC, Westhoff M, Zarth A. Azelastine eye-drops in seasonal allergic conjunctivitis or rhinoconjunctivitis. A double-blind randomized, placebo-controlled study. Allergy 1998;53:857-62.
63. Ciprandi G, Buscaglia S, Pesce G, Passalacqua G, Rihoux JP, Bagnasco M. Ceterizine reduces inflamatory cell recruitmen and ICAM-1 (or CD54) expression on conjunctival epithelium in both early-and late-phase reactions after allergen-specific challenge. J Allergy Clin Immunol 1995;95:612-21.
64. Allergic factors associated with the development of asthma and the influence of cetirizine in a double-blind, randomised, placebo-controlled trial: first results of ETAC. Early Treatment of the Atopic Child. Pediatr Allergy Immunol 1998; 9:116-24.
65. Canonica GW, Parodi Mn, Pesce GP, Bagnasco M. Adhesion molecules on epithelial cells. Allergy Clin Immunology News 1991;(1 A152):128.
66. Ciprandi G, Catrullo A, Cerqueti P, Tosca M, Fiorino N, Canonica GW. Loratadine reduces the expresion of ICAM-1. Allergy 1998;53:545-6.
67. Kjellmann NM. Is there a place for antihistamine in the treatment of perennial asthma? Pediatr Allergy Immunol 1993;4:38-43.
68. Magnussen H, Reuss G, Jorres R, Aurich R. The effect of azelastine exercise-induced asthma. Chest 1988;83:937-40.
69. Patel K. Histmine and exercise-induced asthma. Eur J Clin Res 1991;2:89-96.
70. Ghosh SK, De Vos C, McIlroy I, Patel KR, Effect of cetirizine on exercise-induced asthma. Thorax 1991;46:242-4.
71. Holgate ST, Finnerty JP. Antistamines in asthma. J Allergy Clin Immunol 1989;83:537-47.
72. Melzer EO. The use of anti-H1 drugs in mild asthma. Allergy 1995;50:41-7.
73. Graff-Lonnevig V, Hedlin G. The effect of ketotifen on bronchial hyperreactivity in childood asthma. J Clin Immunol 1985;76:59-63.
74. Ekstrom T, Osterman K, Zettertröm O. Lack of effect loratadine on moderate to severe asthma. Ann Allergy Asthma Immunol 1995;75:287-9.